Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.

Arthritis Res Ther · 2009 · PMC3003523 · PMID 19909548

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Reductions in fatigue and all other PROs with CZP plus MTX remained highly significant throughout the trial, with approximately 50% of patients reporting clinically meaningful reductions by week 52.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.